Should cabergoline be discontinued during pregnancy to address hyperprolactinemia?

During pregnancy, women face many physiological and pharmacological changes, among which the problem of high prolactin is an aspect that requires special attention. Cabergoline is a drug commonly used to treat hyperprolactinemia, and its safety during pregnancy has attracted much attention.

Cabergoline is a dopamine receptor agonist that inhibits prolactin secretion by stimulating dopamineD2 receptors. It effectively reduces prolactin levels in the serum, thereby alleviating the symptoms of hyperprolactinemia.

During pregnancy, the safety of the fetus must first be considered when using any drug. Although cabergoline is effective in treating hyperprolactinemia, its use during pregnancy may have adverse effects on the fetus, such as affecting the normal development of the fetus.

During pregnancy, a woman's hormone levels undergo significant changes, including an increase in prolactin. This is a normal physiological phenomenon to support milk production after delivery. Therefore, whether you need to continue taking medication during pregnancy needs to be weighed based on individual circumstances and doctor's advice.

Based on published information and medical guidance, it is generally recommended that cabergoline be discontinued when a patient becomes pregnant. This is to avoid potential risks that the drug may cause to the fetus and ensure the safe development of the fetus.

After stopping the drug, patients need to regularly monitor prolactin levels to ensure they are within control. This helps to detect and deal with any problems related to high prolactin in a timely manner.

In addition to medication, patients can manage high prolactin problems by making lifestyle adjustments. This includes maintaining a healthy diet, proper exercise, and good sleep habits.